210 related articles for article (PubMed ID: 33351103)
1. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin.
Gergoudis SC; DeFilipp Z; Özbek U; Sandhu KS; Etra AM; Choe HK; Kitko CL; Ayuk F; Aziz M; Baez J; Ben-David K; Bunworasate U; Gandhi I; Hexner EO; Hogan WJ; Holler E; Kasikis S; Kowalyk SM; Lin JY; Merli P; Morales G; Nakamura R; Reshef R; Rösler W; Srinagesh H; Young R; Chen YB; Ferrara JLM; Levine JE
Blood Adv; 2020 Dec; 4(24):6098-6105. PubMed ID: 33351103
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease.
Zewde MG; Morales G; Gandhi I; Özbek U; Aguayo-Hiraldo P; Ayuk F; Baez J; Chanswangphuwana C; Choe H; DeFilipp Z; Etra A; Grupp S; Hexner EO; Hogan W; Javorniczky NR; Kasikis S; Kitko CL; Kowalyk S; Meedt E; Merli P; Nakamura R; Qayed M; Reshef R; Rösler W; Schechter T; Weber D; Wölfl M; Yanik G; Young R; Levine JE; Ferrara JLM; Chen YB
Transplant Cell Ther; 2021 Dec; 27(12):988.e1-988.e7. PubMed ID: 34474163
[TBL] [Abstract][Full Text] [Related]
3. Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin.
Marcondes AM; Hockenbery D; Lesnikova M; Dinarello CA; Woolfrey A; Gernsheimer T; Loghman-Adham M; Gelmont D; Storer B; Hansen JA; Deeg HJ
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1596-1601. PubMed ID: 27223109
[TBL] [Abstract][Full Text] [Related]
4. A Day 14 Endpoint for Acute GVHD Clinical Trials.
Spyrou N; Akahoshi Y; Kowalyk S; Morales G; Beheshti R; Aguayo-Hiraldo P; Al Malki MM; Ayuk F; Bader P; Baez J; Capellini A; Choe H; DeFilipp Z; Eder M; Eng G; Etra A; Gleich S; Grupp SA; Hexner E; Hoepting M; Hogan WJ; Kasikis S; Katsivelos N; Khan A; Kitko CL; Kraus S; Kwon D; Merli P; Portelli J; Qayed M; Reshef R; Schechter T; Vasova I; Wölfl M; Wudhikarn K; Young R; Holler E; Chen YB; Nakamura R; Levine JE; Ferrara JLM
Transplant Cell Ther; 2024 Apr; 30(4):421-432. PubMed ID: 38320730
[TBL] [Abstract][Full Text] [Related]
5. Inpatient Healthcare Resource Utilization, Costs, and Mortality in Adult Patients with Acute Graft-versus-Host Disease, Including Steroid-Refractory or High-Risk Disease, following Allogeneic Hematopoietic Cell Transplantation.
Yu J; Judy JT; Parasuraman S; Sinha M; Weisdorf D
Biol Blood Marrow Transplant; 2020 Mar; 26(3):600-605. PubMed ID: 31678539
[TBL] [Abstract][Full Text] [Related]
6. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD.
Qayed M; Kapoor U; Gillespie S; Westbrook A; Aguayo-Hiraldo P; Ayuk FA; Aziz M; Baez J; Choe H; DeFilipp Z; Etra A; Grupp SA; Hexner E; Holler E; Hogan WJ; Kowalyk S; Merli P; Morales G; Nakamura R; Pulsipher MA; Schechter T; Shah J; Spyrou N; Srinagesh HK; Wölfl M; Yanik G; Young R; Kitko CL; Ferrara JLM; Levine JE
Transplant Cell Ther; 2024 Jun; 30(6):603.e1-603.e11. PubMed ID: 38548227
[TBL] [Abstract][Full Text] [Related]
7. New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD).
Choe H; Ferrara JLM
Expert Opin Ther Targets; 2021 Sep; 25(9):761-771. PubMed ID: 34669521
[TBL] [Abstract][Full Text] [Related]
8. Human-Derived α1-Antitrypsin is Still Efficacious in Heavily Pretreated Patients with Steroid-Resistant Gastrointestinal Graft-versus-Host Disease.
Giannoni L; Morin F; Robin M; Peyneau M; Schlageter MH; Desmier D; Pagliuca S; Sutra Del Galy A; Sicre de Fontbrune F; Xhaard A; Dhedin N; Moins-Teisserenc H; Peffault de Latour R; Socié G; Michonneau D
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1620-1626. PubMed ID: 32454215
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
[TBL] [Abstract][Full Text] [Related]
10. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.
Major-Monfried H; Renteria AS; Pawarode A; Reddy P; Ayuk F; Holler E; Efebera YA; Hogan WJ; Wölfl M; Qayed M; Hexner EO; Wudhikarn K; Ordemann R; Young R; Shah J; Hartwell MJ; Chaudhry MS; Aziz M; Etra A; Yanik GA; Kröger N; Weber D; Chen YB; Nakamura R; Rösler W; Kitko CL; Harris AC; Pulsipher M; Reshef R; Kowalyk S; Morales G; Torres I; Özbek U; Ferrara JLM; Levine JE
Blood; 2018 Jun; 131(25):2846-2855. PubMed ID: 29545329
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
Al Malki MM; London K; Baez J; Akahoshi Y; Hogan WJ; Etra A; Choe H; Hexner E; Langston A; Abhyankar S; Ponce DM; DeFilipp Z; Kitko CL; Adekola K; Reshef R; Ayuk F; Capellini A; Chanswangphuwana C; Eder M; Eng G; Gandhi I; Grupp S; Gleich S; Holler E; Javorniczky NR; Kasikis S; Kowalyk S; Morales G; Özbek U; Rösler W; Spyrou N; Yanik G; Young R; Chen YB; Nakamura R; Ferrara JLM; Levine JE
Blood Adv; 2023 Sep; 7(17):5189-5198. PubMed ID: 37235690
[TBL] [Abstract][Full Text] [Related]
12. Altered Serum Alpha1-Antitrypsin Protease Inhibition before and after Clinical Hematopoietic Stem Cell Transplantation: Association with Risk for Non-Relapse Mortality.
Brami I; Zuckerman T; Ram R; Avni B; Peretz G; Ostrovsky D; Lior Y; Faour C; McElvaney O; McElvaney NG; Lewis EC
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203593
[TBL] [Abstract][Full Text] [Related]
13. Steroid-Sensitive, but Not Steroid-Dependent or Steroid-Resistant Acute Graft-versus-Host Disease, Results in Similar Infection Risk as No Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation.
Young JH; El Jurdi N; Rayes A; MacMillan ML; Holtan SG; Cao Q; Witte J; Arora M; Weisdorf DJ
Transplant Cell Ther; 2022 Aug; 28(8):509.e1-509.e11. PubMed ID: 35577324
[TBL] [Abstract][Full Text] [Related]
14. Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease.
Kasikis S; Etra A; Levine JE
BioDrugs; 2021 Jan; 35(1):19-33. PubMed ID: 33201499
[TBL] [Abstract][Full Text] [Related]
15. Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease.
Stenger E; Giver CR; Langston A; Kota D; Das PK; Chinnadurai R; Galipeau J; Waller EK; Qayed M
Front Immunol; 2022; 13():959658. PubMed ID: 36189324
[TBL] [Abstract][Full Text] [Related]
16. Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores.
Rozmus J; Levine JE; Schultz KR
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):149-154. PubMed ID: 38066854
[TBL] [Abstract][Full Text] [Related]
17. α
Magenau JM; Goldstein SC; Peltier D; Soiffer RJ; Braun T; Pawarode A; Riwes MM; Kennel M; Antin JH; Cutler CS; Ho VT; Alyea EP; Parkin BL; Yanik GA; Choi SW; Lewis EC; Dinarello CA; Koreth J; Reddy P
Blood; 2018 Mar; 131(12):1372-1379. PubMed ID: 29437593
[TBL] [Abstract][Full Text] [Related]
18. Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation.
Hotta M; Satake A; Yoshimura H; Fujita S; Katayama Y; Ota S; Hanamoto H; Oyake T; Ito S; Okada M; Nakanishi T; Ito T; Ishii K; Nomura S
Transplant Cell Ther; 2021 Aug; 27(8):660.e1-660.e8. PubMed ID: 33989832
[TBL] [Abstract][Full Text] [Related]
19. Acute GVHD: New approaches to clinical trial monitoring.
Spyrou N; Levine JE; Ferrara JLM
Best Pract Res Clin Haematol; 2022 Dec; 35(4):101400. PubMed ID: 36517119
[TBL] [Abstract][Full Text] [Related]
20. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis.
Akahoshi Y; Spyrou N; Hoepting M; Aguayo-Hiraldo P; Ayuk F; Chanswangphuwana C; Choe HK; Eder M; Etra AM; Grupp SA; Hexner EO; Hogan WJ; Kitko CL; Kraus S; Al Malki MM; Merli P; Qayed M; Reshef R; Schechter T; Ullrich E; Vasova I; Wölfl M; Zeiser R; Baez J; Beheshti R; Eng G; Gleich S; Kasikis S; Katsivelos N; Kowalyk S; Morales G; Young R; DeFilipp Z; Ferrara JLM; Levine JE; Nakamura R
Blood Adv; 2024 Apr; 8(8):2047-2057. PubMed ID: 38324721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
